Skip to content

US · TNGX · BIOTECHNOLOGY

Tango Therapeutics, Inc. (TNGX) intrinsic value and stock valuation

$21.73as of 2026-11-21 · Mkt cap 3.37B

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Tango Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values TNGX with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from TNGX’s statements →

Tango Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Boston, MA 02215 tangotx.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$62.4M+52.1% 5y CAGRd
20192025
Net income
-$-101.59M
20192025
Free cash flow
-$-139.93M
20192025
Total equity
$346.2M+55.1% 5y CAGRd
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$62.4M$42.1M$36.5M$24.9M$37M
Operating income-$-111.29M-$-145.59M-$-114.17M-$-111.07M-$-58.19M
Net income-$-101.59M-$-130.3M-$-101.74M-$-108.18M-$-58.23M
EPSd-$-874.49K-$-1.19M-$-1.08M-$-1.23M-$-937.53K
Operating cash flow-$-138.89M-$-131.5M-$-117.98M-$-109.08M-$-59.53M
Capital expenditure-$-1.05M-$-750K-$-1.53M-$-7.69M-$-1.84M
Free cash flow-$-139.93M-$-132.25M-$-119.51M-$-116.77M-$-61.36M
Total assets$398.7M$316.5M$402.6M$436.5M$500.2M
Total debt$33.6M$36.5M$38.9M$41.1M$1.5M
Net debt-$-78.71M-$-33.04M-$-27.46M-$-18.84M-$-141.24M
Total equity$346.2M$199.5M$253.1M$249.5M$344.8M
Cash and short-term investments$343.1M$257.9M$336.9M$366.1M$485.3M
Income statement
20252024202320222021
Revenue$62.4M$42.1M$36.5M$24.9M$37M
Cost of revenue$2.28M$0.00$0.00$0.00$0.00
Gross profit$60.1M$42.1M$36.5M$24.9M$37M
Research and development expenses$132.2M$143.9M$115.2M$105.9M$77.6M
Selling, general and administrative expenses$41.5M$43.8M$35.5M$30M$17.6M
Other expenses-$-2.28M$0.00$0.00$0.00$0.00
Operating expenses$171.4M$187.7M$150.7M$135.9M$95.2M
Cost and expenses$173.7M$187.7M$150.7M$135.9M$95.2M
Interest income$5.63M$7.89M$6.62M$1.46M$490K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$2.28M$2.5M$2.42M$1.61M$900K
Ebitda-$-99.31M-$-127.59M-$-99.19M-$-106.51M-$-57.05M
Operating income-$-111.29M-$-145.59M-$-114.17M-$-111.07M-$-58.19M
Total other income/expenses, net$9.7M$15.5M$12.6M$2.95M$250K
Income before tax-$-101.59M-$-130.09M-$-101.61M-$-108.12M-$-57.94M
Income tax expense$0.00$210K$130K$50K$290K
Net income-$-101.59M-$-130.3M-$-101.74M-$-108.18M-$-58.23M
Weighted average shares outstanding$116.2M$109.2M$94.6M$87.8M$62.1M
Weighted average diluted shares outstanding$116.2M$109.2M$94.6M$87.8M$62.1M
Balance sheet
20252024202320222021
Cash and short-term investments$343.1M$257.9M$336.9M$366.1M$485.3M
Net receivables$0.00$0.00$0.00$2M$2M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$353.8M$266.3M$346.5M$375.3M$492.3M
Property, plant and equipment, net$42.5M$47.6M$53.4M$57.8M$6.09M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$44.9M$50.2M$56M$61.2M$7.82M
Total assets$398.7M$316.5M$402.6M$436.5M$500.2M
Accounts payable$1.18M$1.6M$2.79M$4.45M$3.23M
Short-term debt$2.74M$2.45M$2.08M$1.77M$1.5M
Deferred revenue$0.00$17.6M$25.7M$31.8M$26M
Total current liabilities$21.7M$38.2M$45.9M$55.6M$40.7M
Long-term debt$30.8M$34M$36.8M$39.4M$0.00
Deferred revenue, non-current$0.00$44.8M$66.7M$92.1M$114.7M
Total non-current liabilities$30.8M$78.8M$103.5M$131.5M$114.7M
Capital lease obligations$2.74M$36.5M$38.9M$41.1M$1.5M
Total liabilities$52.5M$117M$149.5M$187M$155.4M
Common stock$140K$110K$100K$90K$90K
Retained earnings-$-603.15M-$-501.56M-$-371.26M-$-269.51M-$-161.34M
Accumulated other comprehensive income (loss)$220K$340K$190K-$-3.71M-$-770K
Total equity$346.2M$199.5M$253.1M$249.5M$344.8M
Total investments$230.9M$188.4M$270.5M$306.2M$342.5M
Total debt$33.6M$36.5M$38.9M$41.1M$1.5M
Net debt-$-78.71M-$-33.04M-$-27.46M-$-18.84M-$-141.24M
Cash flow statement
20252024202320222021
Net income-$-101.59M-$-130.3M-$-101.74M-$-108.18M-$-58.23M
Depreciation and amortization$2.28M$2.5M$2.42M$1.61M$900K
Stock-based compensation$26.4M$28.9M$19.1M$14.2M$7.83M
Change in working capital-$-67.2M-$-31.75M-$-37.97M-$-18.49M-$-11.35M
Accounts receivable$0.00$0.00$2M$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-820K-$-1.18M-$-1.71M$1.1M$1.23M
Net cash provided by operating activities-$-138.89M-$-131.5M-$-117.98M-$-109.08M-$-59.53M
Investments in property, plant and equipment-$-1.05M-$-750K-$-1.53M-$-7.69M-$-1.84M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-40.87M$86.1M$41.4M$26.4M-$-183.43M
Common stock issued$222.5M$41.7M$80M$0.00$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$222.5M$47.7M$82.4M$1.61M$357.3M
Net change in cash$42.8M$2.29M$5.85M-$-81.07M$114.4M
Cash at end of period$114.9M$72.1M$69.8M$64M$145M
Operating cash flow-$-138.89M-$-131.5M-$-117.98M-$-109.08M-$-59.53M
Capital expenditure-$-1.05M-$-750K-$-1.53M-$-7.69M-$-1.84M
Free cash flow-$-139.93M-$-132.25M-$-119.51M-$-116.77M-$-61.36M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Tango Therapeutics, Inc.

        Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.

        CEO
        Malte Peters
        Employees
        137
        Beta
        1.13

        Explore

        Frequently asked questions

        What is the intrinsic value of Tango Therapeutics, Inc. (TNGX)?

        Tango Therapeutics, Inc. (TNGX) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is TNGX undervalued?

        TNGX trades at a price of $21.73 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.